CGTN
22.9.2020 08:50:08 CEST | Business Wire | Press release
The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005948/en/
The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide.
"What kind of UN does the world need and what role should it play in the post-pandemic era?"
Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link.
The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the progress of the times and the most important principle in the UN Charter.
The organization should be committed to achieving shared growth through consultation and collaboration, he stressed, calling on countries around the world to maintain common security and share the fruits of development.
Xi called for increased representation and a louder voice for developing countries in the UN and upholding the purposes and principles of the UN Charter.
He said the UN should promote international cooperation and lead efforts to solve various problems in the world. It should advance security, development and human rights in a balanced manner and give more emphasis to development on its global agenda, he added.
Uphold multilateralism, enhance cooperation
"During the 75 years of the UN, the world has seen rapid progress of the human society, profound changes in international situations and fast development of multilateralism," the Chinese president said.
He reiterated China's commitment to multilateralism and determination to safeguard the international system with the UN at its core.
As the international community strives to find solutions to problems faced by mankind, "multilateralism" has been a buzzword during the 75th session of the UN General Assembly that opened last week.
UN Secretary-General Antonio Guterres urged world leaders to work together at a time when there is a surplus of multilateral challenges and a deficit of solutions. "The future we want, the United Nations we need, is reaffirming our collective commitment to multilateralism is under way," he said.
Indeed, the need for more – and more effective – multilateralism is well known, he said, stressing that national sovereignty – a pillar of the Charter of the United Nations – goes hand‑in‑hand with enhanced international cooperation, based on common values and shared responsibilities for progress.
Russian Foreign Minister Sergei Lavrov said the international community is becoming increasingly fragmented, adding that "this is largely attributable to the fact that some countries are meddling in the domestic affairs of other states and imposing unilateral sanctions."
"The world is tired of dividing lines, of separating states into friends and foes, and demands stepping up all-encompassing and inclusive mutual assistance and cooperation," he said.
German Chancellor Angela Merkel said the interests of individual member states had "too often" forced the UN to lag behind its ideals.
"Those who believe that they can get along better alone are mistaken. Our well-being is something that we share – our suffering too. We are one world," she told the General Assembly.
While customs and cultures may differ, cooperation requires unstinting efforts to overcome misunderstanding, and beyond that, to embrace respect, European Council President Charles Michel noted.
"It is not our rhetoric that will matter," he said, but rather, the collective actions taken to foster a better world.
The theme of this year's UN high-level sessions is "The Future We Want, the UN We Need: Reaffirming Our Collective Commitment to Multilateralism." It echoes Xi's consistent call to build a community with a shared future for mankind.
Meanwhile, 48 former UN and government officials from around the world released an open letter – "A Time for Renewal: Calling for a Strengthened Multilateral System" – last Friday, expressing their hope that the UN would be transformed into a "stronger, more accountable, inclusive multilateral system."
"There is an urgent need for an explicit recognition by global leaders that we are at a turning point and must act decisively to defend and rejuvenate multilateralism," they said, stressing that recovery from the COVID-19 pandemic needs national leadership and effective global cooperation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005948/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
